Voices
Jan Micheal Werner: Using ¹⁸F-FET PET and MRI to Identify Responders to Regorafenib in Recurrent Glioma
Jan Micheal Werner/LinkedIn

Jan Micheal Werner: Using ¹⁸F-FET PET and MRI to Identify Responders to Regorafenib in Recurrent Glioma

Jan Micheal Werner, Clinician scientist of Department of Neurology at the University Hospital Cologne, shared a post on LinkedIn about an article he co-authored published on The Journal of Nuclear Medicine:

“Happy to share our recent publication from University Hospital Cologne and Forschungszentrum Jülich on the ‘Assessment of Response to Regorafenib in Patients with Glioma Relapse using 18F-FET PET and MRI’, just published in the The Journal of Nuclear Medicine – JNM

In brief, we demonstrate that 18F-FET PET parameters are clinically valuable for identifying responders to regorafenib early after treatment initiation.

Many thanks to Norbert Galldiks, Philipp Lohmann and all co-authors.”

Title: Assessment of Response to Regorafenib in Patients with Glioma Relapse using 18F-FET PET and MRI

Authors: Jan-Michael Werner, Philipp Lohmann, Christoph Kabbasch, Michael M. Wollring, Caroline Tscherpel, Lukas Goertz, Jurij Rosen, Gabriele Stoffels, Roland Goldbrunner, Felix M. Mottaghy, Karl-Josef Langen, Gereon R. Fink, Norbert Galldiks

Read the full article on The Journal of Nuclear Medicine.

Jan Micheal Werner: Using ¹⁸F-FET PET and MRI to Identify Responders to Regorafenib in Recurrent Glioma

More posts about Glioma.

cancer Caroline Tscherpel Christoph Kabbasch Felix M. Mottaghy Gabriele Stoffels Gereon R. Fink glioma Jan-Michael Werner Jurij Rosen Karl-Josef Langen Lukas Goertz Michael M. Wollring NeuroOncology Norbert Galldiks OncoDaily Oncology Philipp Lohmann Roland Goldbrunner